Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Phase 3 study highlights Xarelto’s potential in pediatric Fontan procedure patients 

By Brian Buntz | October 5, 2021

JanssenDrugs that work well in adults don’t always translate well for treating pediatric patients.

The problem has inspired clinicians such as the pediatric cardiologist Dr. Brian McCrindle at the Hospital for Sick Children in Toronto to work with the pharma industry on trials focused on pediatric patient populations and introduce newer agents to clinical practice. Traditionally, the process of selecting drugs for younger populations has been “somewhat imperfect and somewhat derived from experience in adult patients,” McCrindle said.

Most recently, McCrindle was the co-author of a preprint study published in the Journal of the American Heart Association investigating the use of rivaroxaban (Xarelto) from Janssen in patients who underwent a surgical procedure to correct a congenital heart defect.

Blood thinners such as rivaroxaban and aspirin — acetylsalicylic acid (ASA) — can reduce the risk of thrombosis and its potential to cause stroke or other devastating complications.

The Phase 3 UNIVERSE study found that rivaroxaban in an oral suspension formulation was comparable to treatment with aspirin. Additionally, rivaroxaban recipients had fewer blood clots and clinical events associated with blood clots than recipients of aspirin.

“My specific interest in the rivaroxaban study is that it’s one of a group of new anticoagulant agents that have some practice superiority,” McCrindle said.

Cardiologists have traditionally focused on using vitamin-K antagonists for anticoagulation. But such drugs, including warfarin, are problematic for pediatric age groups, given the potential drug-drug and drug-food interactions in younger patients. In addition, it is difficult to maintain the optimal therapeutic dose of such drugs in pediatric patients, requiring them to receive frequent blood monitoring. In addition, warfarin can have significant adverse effects in pediatric patients.

Launching a clinical trial for patients treated with the Fontan procedure, indicated in patients with a functional single ventricle in the heart, had certain challenges.

First, treating patients with a functional single ventricle itself remains challenging acutely and in the long term. “Single ventricle is definitely one of the more severe types of congenital heart disease that pediatric cardiologists would see,” McCrindle said.

Typically, there are two ventricles at the bottom of the heart. One pumps blood to the body while the other pumps to the lungs. When a patient has a single functional ventricle, the Fontan procedure can take advantage of the fact that the blood vessels flowing to the lungs are a “low resistance circuit,” McCrindle said. “You can take advantage of that and create a circulation whereby the ventricle that you do have, you dedicate to pumping blood to the body,” he said. Blood coming from the veins then flows passively into the lungs.

The single ventricle is rare, representing approximately 7.7% of congenital heart disease diagnosed in childhood, according to a 2002 assessment in Progress in Pediatric Cardiology. “We only enrolled patients in the immediate period after their Fontan operation, so this created a very limited pool of available subjects,” McCrindle said.

For that reason, the study required extensive collaboration between investigators across various medical centers.

Even still, the study was not powered to reliably detect the clinical superiority of rivaroxaban over aspirin. “Performing such a study would be next to impossible, given the low event rates and the rarity of the population, and how long you might have to observe them for before you got enough events,” McCrindle said.

The study could pave the way to expanded use of rivaroxaban in patients who have had the Fontan procedure, given its performance relative to aspirin in the study.

Having “some data is always better than no data,” McCrindle said. “And even though the results of the study are not statistically significant, I think the differences are clinically important.”


Filed Under: Cardiovascular, clinical trials, Drug Discovery
Tagged With: acetylsalicylic acid, aspirin, Brian McCrindle, Journal of the American Heart Association, pediatric cardiology, rivaroxaban, Xarelto
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE